Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Deborah Cannon is active.

Publication


Featured researches published by Deborah Cannon.


PLOS Pathogens | 2009

Isolation of Genetically Diverse Marburg Viruses from Egyptian Fruit Bats

Jonathan S. Towner; Brian R. Amman; Tara K. Sealy; Serena A. Carroll; James A. Comer; Alan Kemp; Robert Swanepoel; Christopher D. Paddock; Stephen Balinandi; Marina L. Khristova; Pierre Formenty; César G. Albariño; David Miller; Zachary Reed; John Kayiwa; James N. Mills; Deborah Cannon; Patricia W. Greer; Emmanuel Byaruhanga; Eileen C. Farnon; Patrick Atimnedi; Samuel Okware; Edward Katongole-Mbidde; Robert Downing; Jordan W. Tappero; Sherif R. Zaki; Thomas G. Ksiazek; Stuart T. Nichol; Pierre E. Rollin

In July and September 2007, miners working in Kitaka Cave, Uganda, were diagnosed with Marburg hemorrhagic fever. The likely source of infection in the cave was Egyptian fruit bats (Rousettus aegyptiacus) based on detection of Marburg virus RNA in 31/611 (5.1%) bats, virus-specific antibody in bat sera, and isolation of genetically diverse virus from bat tissues. The virus isolates were collected nine months apart, demonstrating long-term virus circulation. The bat colony was estimated to be over 100,000 animals using mark and re-capture methods, predicting the presence of over 5,000 virus-infected bats. The genetically diverse virus genome sequences from bats and miners closely matched. These data indicate common Egyptian fruit bats can represent a major natural reservoir and source of Marburg virus with potential for spillover into humans.


PLOS Pathogens | 2012

Seasonal Pulses of Marburg Virus Circulation in Juvenile Rousettus aegyptiacus Bats Coincide with Periods of Increased Risk of Human Infection

Brian R. Amman; Serena A. Carroll; Zachary Reed; Tara K. Sealy; Stephen Balinandi; Robert Swanepoel; Alan Kemp; Bobbie R. Erickson; James A. Comer; Shelley Campbell; Deborah Cannon; Marina L. Khristova; Patrick Atimnedi; Christopher D. Paddock; Rebekah J. Kent Crockett; Timothy D. Flietstra; Kelly L. Warfield; Robert Unfer; Edward Katongole-Mbidde; Robert Downing; Jordan W. Tappero; Sherif R. Zaki; Pierre E. Rollin; Thomas G. Ksiazek; Stuart T. Nichol; Jonathan S. Towner

Marburg virus (family Filoviridae) causes sporadic outbreaks of severe hemorrhagic disease in sub-Saharan Africa. Bats have been implicated as likely natural reservoir hosts based most recently on an investigation of cases among miners infected in 2007 at the Kitaka mine, Uganda, which contained a large population of Marburg virus-infected Rousettus aegyptiacus fruit bats. Described here is an ecologic investigation of Python Cave, Uganda, where an American and a Dutch tourist acquired Marburg virus infection in December 2007 and July 2008. More than 40,000 R. aegyptiacus were found in the cave and were the sole bat species present. Between August 2008 and November 2009, 1,622 bats were captured and tested for Marburg virus. Q-RT-PCR analysis of bat liver/spleen tissues indicated ∼2.5% of the bats were actively infected, seven of which yielded Marburg virus isolates. Moreover, Q-RT-PCR-positive lung, kidney, colon and reproductive tissues were found, consistent with potential for oral, urine, fecal or sexual transmission. The combined data for R. aegyptiacus tested from Python Cave and Kitaka mine indicate low level horizontal transmission throughout the year. However, Q-RT-PCR data show distinct pulses of virus infection in older juvenile bats (∼six months of age) that temporarily coincide with the peak twice-yearly birthing seasons. Retrospective analysis of historical human infections suspected to have been the result of discrete spillover events directly from nature found 83% (54/65) events occurred during these seasonal pulses in virus circulation, perhaps demonstrating periods of increased risk of human infection. The discovery of two tags at Python Cave from bats marked at Kitaka mine, together with the close genetic linkages evident between viruses detected in geographically distant locations, are consistent with R. aegyptiacus bats existing as a large meta-population with associated virus circulation over broad geographic ranges. These findings provide a basis for developing Marburg hemorrhagic fever risk reduction strategies.


Emerging Infectious Diseases | 2010

Proportion of Deaths and Clinical Features in Bundibugyo Ebola Virus Infection, Uganda

Adam MacNeil; Eileen C. Farnon; Joseph F. Wamala; Samuel Okware; Deborah Cannon; Zachary Reed; Jonathan S. Towner; Jordan W. Tappero; Julius J. Lutwama; Robert Downing; Stuart T. Nichol; Thomas G. Ksiazek; Pierre E. Rollin

The first known Ebola hemorrhagic fever (EHF) outbreak caused by Bundibugyo Ebola virus occurred in Bundibugyo District, Uganda, in 2007. Fifty-six cases of EHF were laboratory confirmed. Although signs and symptoms were largely nonspecific and similar to those of EHF outbreaks caused by Zaire and Sudan Ebola viruses, proportion of deaths among those infected was lower (≈40%).


Journal of Virology | 2011

Rift Valley Fever Virus Vaccine Lacking the NSs and NSm Genes Is Safe, Nonteratogenic, and Confers Protection from Viremia, Pyrexia, and Abortion following Challenge in Adult and Pregnant Sheep

Brian H. Bird; Louis H. Maartens; Shelley Campbell; Baltus J. Erasmus; Bobbie R. Erickson; Kimberly A. Dodd; Christina F. Spiropoulou; Deborah Cannon; Clifton P. Drew; Barbara Knust; Anita K. McElroy; Marina L. Khristova; César G. Albariño; Stuart T. Nichol

ABSTRACT Rift Valley fever virus (RVFV) is a mosquito-borne human and veterinary pathogen causing large outbreaks of severe disease throughout Africa and the Arabian Peninsula. Safe and effective vaccines are critically needed, especially those that can be used in a targeted one-health approach to prevent both livestock and human disease. We report here on the safety, immunogenicity, and efficacy of the ΔNSs-ΔNSm recombinant RVFV (rRVFV) vaccine (which lacks the NSs and NSm virulence factors) in a total of 41 sheep, including 29 timed-pregnant ewes. This vaccine was proven safe and immunogenic for adult animals at doses ranging from 1.0 × 103 to 1.0 × 105 PFU administered subcutaneously (s.c.). Pregnant animals were vaccinated with 1.0 × 104 PFU s.c. at day 42 of gestation, when fetal sensitivity to RVFV vaccine-induced teratogenesis is highest. No febrile reactions, clinical illness, or pregnancy loss was observed following vaccination. Vaccination resulted in a rapid increase in anti-RVFV IgM (day 4) and IgG (day 7) titers. No seroconversion occurred in cohoused control animals. A subset of 20 ewes progressed to full-term delivery after vaccination. All lambs were born without musculoskeletal, neurological, or histological birth defects. Vaccine efficacy was assessed in 9 pregnant animals challenged at day 122 of gestation with virulent RVFV (1.0 × 106 PFU intravenously). Following challenge, 100% (9/9) of the animals were protected, progressed to full term, and delivered healthy lambs. As expected, all 3 sham-vaccinated controls experienced viremia, fetal death, and abortion postchallenge. These results demonstrate that the ΔNSs-ΔNSm rRVFV vaccine is safe and nonteratogenic and confers high-level protection in sheep.


The Journal of Infectious Diseases | 2001

A cohort study of health care workers to assess nosocomial transmissibility of Nipah virus, Malaysia, 1999

Anthony W. Mounts; Hanjeet Kaur; Umesh D. Parashar; Thomas G. Ksiazek; Deborah Cannon; Jt Arokiasamy; Larry J. Anderson; Munn Sann Lye

During 1998-1999, an outbreak of Nipah virus encephalitis occurred in Malaysia. To assess the possibility of nosocomial transmission, 338 health care workers (HCWs) exposed and 288 HCWs unexposed to outbreak-related patients were surveyed, and their serum samples were tested for anti-Nipah virus antibody. Needlestick injuries were reported by 12 (3%) HCWs, mucosal surface exposure to body fluids by 39 (11%), and skin exposure to body fluids by 89 (25%). No encephalitis occurred in either group. Three exposed and no unexposed HCWs tested positive by EIA for IgG antibodies. It is likely that these 3 were false positives; no IgM response occurred, and the serum samples were negative for anti-Nipah virus neutralizing antibodies. The risk of nosocomial transmission of Nipah virus appears to be low; however, given the high case-fatality rate and the presence of virus in respiratory secretions and urine of some patients, standard and droplet infection-control practices should be maintained with these patients.


Virology | 2013

Genomic analysis of filoviruses associated with four viral hemorrhagic fever outbreaks in Uganda and the Democratic Republic of the Congo in 2012.

César G. Albariño; Trevor Shoemaker; Marina L. Khristova; Joseph F. Wamala; J.J. Muyembe; Stephen Balinandi; Alex Tumusiime; Shelley Campbell; Deborah Cannon; Aridth Gibbons; Éric Bergeron; Brian H. Bird; Kimberly A. Dodd; Christina F. Spiropoulou; Bobbie R. Erickson; Lisa Wiggleton Guerrero; Barbara Knust; Stuart T. Nichol; Pierre E. Rollin; Ute Ströher

In 2012, an unprecedented number of four distinct, partially overlapping filovirus-associated viral hemorrhagic fever outbreaks were detected in equatorial Africa. Analysis of complete virus genome sequences confirmed the reemergence of Sudan virus and Marburg virus in Uganda, and the first emergence of Bundibugyo virus in the Democratic Republic of the Congo.


Clinical Infectious Diseases | 2016

Ebola Virus Persistence in Semen of Male Survivors

Timothy M. Uyeki; Bobbie R. Erickson; Shelley Brown; Anita K. McElroy; Deborah Cannon; Aridth Gibbons; Tara K. Sealy; Markus H. Kainulainen; Colleen S. Kraft; Aneesh K. Mehta; G. Marshall Lyon; Jay B. Varkey; Bruce S. Ribner; Richard T. Ellison; Ellie Carmody; Gerard J. Nau; Christina F. Spiropoulou; Stuart T. Nichol; Ute Ströher

We investigated the duration of Ebola virus (EBOV) RNA and infectious EBOV in semen specimens of 5 Ebola virus disease (EVD) survivors. EBOV RNA and infectious EBOV was detected by real-time RT-PCR and virus culture out to 290 days and 70 days, respectively, after EVD onset.


Emerging Infectious Diseases | 2012

Solid Organ Transplant–associated Lymphocytic Choriomeningitis, United States, 2011

Adam MacNeil; Ute Ströher; Eileen C. Farnon; Shelley Campbell; Deborah Cannon; Christopher D. Paddock; Clifton P. Drew; Matthew J. Kuehnert; Barbara Knust; Robert Gruenenfelder; Sherif R. Zaki; Pierre E. Rollin; Stuart T. Nichol

Lymphocytic choriomeningitis virus (LCMV) is carried by rodents. In very rare instances, it has been transmitted from person-to-person by organ transplantation. In 2011, a total of 14 organ recipients were infected with the virus, of which 11 died in the United States. The 4 most recent patients received organs from the same donor, which resulted in 2 deaths. Only after these 4 organ recipients became sick was it discovered that the donor had been exposed to rodents. Had this exposure been known before transplantation, the organ recipients may have been more closely monitored. Early diagnosis and treatment might have improved their chances of survival. Although organ donor screening reduces the risk for transmission of some viruses, it is not possible to screen for all possible viruses, including LCMV. For patients who get severely ill after receiving a transplant, clinicians should add LCMV infection to their list of possible causes.


Emerging Infectious Diseases | 2016

Nipah Virus Transmission from Bats to Humans Associated with Drinking Traditional Liquor Made from Date Palm Sap, Bangladesh, 2011-2014.

M. Saiful Islam; Hossain M.S. Sazzad; Syed Moinuddin Satter; Sharmin Sultana; M. Jahangir Hossain; M.K. Hasan; Mahmudur Rahman; Shelley Campbell; Deborah Cannon; Ute Ströher; Peter Daszak; Stephen P. Luby

Interventions that prevent bat access to this sap might prevent these infections.


Emerging Infectious Diseases | 2014

Lymphocytic choriomeningitis virus in employees and mice at multipremises feeder-rodent operation, United States, 2012.

Barbara Knust; Ute Ströher; Laura S. Edison; César G. Albariño; Jodi Lovejoy; Emilian Armeanu; Jennifer House; Denise Cory; Clayton Horton; Kathy L. Fowler; Jessica Austin; John Poe; Kraig E. Humbaugh; Lisa Wiggleton Guerrero; Shelley Campbell; Aridth Gibbons; Zachary Reed; Deborah Cannon; Craig Manning; Brett W. Petersen; Douglas Metcalf; Bret Marsh; Stuart T. Nichol; Pierre E. Rollin

Outbreaks can be prevented with strict biosecurity and microbiological monitoring.

Collaboration


Dive into the Deborah Cannon's collaboration.

Top Co-Authors

Avatar

Stuart T. Nichol

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Pierre E. Rollin

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Ute Ströher

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Bobbie R. Erickson

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Shelley Campbell

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Barbara Knust

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

César G. Albariño

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Christina F. Spiropoulou

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Thomas G. Ksiazek

University of Texas Medical Branch

View shared research outputs
Top Co-Authors

Avatar

Aridth Gibbons

Centers for Disease Control and Prevention

View shared research outputs
Researchain Logo
Decentralizing Knowledge